Investing with top performing managers after a great run is probably a bad idea, according to a new study of long-term hedge fund performance.» Read More
CNBC's David Faber reports Allergan has filed a lawsuit against Valeant Pharmaceuticals and Pershing Square's Bill Ackman alleging a violation of federal securities laws.
Some of Thursday's midday movers:
July 31- Canada's Valeant Pharmaceuticals International Inc, embroiled in a bitter battle to take over Botox-maker Allergan Inc, on Thursday cut its 2014 and 2015 profit forecasts, sending shares 10 percent lower.
CNBC's David Faber reports the latest details of Valeant Pharmaceuticals bid for Allergan.
July 31- Canada's Valeant Pharmaceuticals International Inc, embroiled in a bitter battle to take over Botox-maker Allergan Inc, cut its full-year profit and revenue forecasts to reflect the sale of its rights to several skincare products.
Companies like Chipotle and Philip Morris have been discussing price hikes that would give bottom lines a whole new driver. USAT reports.
July 25- Allergan Inc, known best for its Botox wrinkle treatment, said on Friday that European Union regulators had recommended use of its eye drug Ozurdex be extended to treat patients with diabetic macular edema.
A Republican congressman will pressure the Securities and Exchange Commission for reforms after Bill Ackman's efforts to take over Allergan.
WASHINGTON, July 24- A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.
Pershing Square Capital Management clients aren't very concerned about Herbalife's big gain yesterday.
Bill Ackman, head of Pershing Square Capital Management, said his firm's presentation of a Herbalife investigation will "expose incredible fraud."
Stocks declined Monday as global disapproval of Russia increased after the downing of a passenger plane in Ukraine.
July 21- Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc, said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.
Bill Ackman, Pershing Square, explains why he is not upping his bid for Allergan. The market clearly thinks the chance of Valeant buying Allergan has gone up, says Ackman.
CNBC's Meg Tirrell reports Allergan posted Q2 results that beat on earnings and sales, as the company announced its restructuring plans, which may include an acquisition of its own.
Some of Monday's midday movers:
NEW YORK, July 21- U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday that it would cut 13 percent of its global workforce as part of a restructuring meant to boost profits over the next six years.
CNBC's David Faber reports Allergan is cutting 13 percent of its workforce and Valeant complains to the SEC and Canadian regulators about Allergan statements.
CNBC's David Faber reports activist investor Elliot Management reportedly has taken and more than $1 billion stake in EMC. And Allergan announces plans to cut 1,500 jobs as it continues fighting a takeover from Valeant.